Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation

Bone Marrow Transplantation

Volumn 37, Issue 8, 2006, Pages 719-724

  Pavone, V ^a,b   Gaudio, F ^a   Console, G ^c   Vitolo, U ^d   Iacopino, P ^c   Guarini, A ^a   Liso, V ^a   Perrone, T ^a   Liso, A ^e  

^a UNIVERSITY OF BARI   (Italy)

^b Hematology Department   (Italy)

^c Bone Marrow Transplant Unit   (Italy)

^d Turin Hospital   (Italy)

^e UNIVERSITY OF FOGGIA   (Italy)

Author keywords

CD34 + cells; Malignant lymphoma; Mobilizing regimens; Stem cells

Indexed keywords

BLEOMYCIN; CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG MEGADOSE; FEMALE; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; STEM CELL MOBILIZATION;

ADULT; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; RETROSPECTIVE STUDIES; STEM CELLS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33645703790     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705298     Document Type: Article

References (43)

1. Marcoullis G, Mehta J, Treleaven J. Autologous bone marrow and peripheral blood stem cell transplantation in haematological malignancies: Current status. Med Oncol 1995; 12: 209-218.
2. Strehl J, Mey U, Glasmacher A, Djulbegovic B, Mayr C, Gorschluter M. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: A meta-analysis. Haematologica 2003; 88: 1304-1315.
3. Seropian S, Bahceci E, Cooper DL. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma. Bone Marrow Transplant 2003; 32: 763-769.
4. Kewalramani T, Nimer SD, Zelenetz AD, Malhotra S, Qin J, Yahalom J et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2003; 32: 673-679.
5. Lin TS, Copelan EA. Autologous stem cell transplantation for non-Hodgkin's lymphoma. Curr Hematol Rep 2003; 2: 310-315.
6. van Besien K, Loberiza Jr FR, Bajorunaite R, Armitage JO, Bashey A, Burns LJ et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521-3529.
7. Nademanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR, Snyder DS et al. High dose therapy followed by autologous peripheral blood stem cell transplantation for patients with Hodgkin's disease and non-Hodgkin's Lymphoma using unprimed and granulocyte colony stimulating factor-mobilized peripheral blood stem cells. J Clin Oncol 1994; 12: 2176-2186.
8. Mahmoud H, Fahmy O, Kamel A, Kamel M, El-Haddad A, El-Kadi D et al. Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 355-358.
9. Fauser AA, Basara N, Blau IW, Kiehl MG. A comparative study of peripheral blood stem cell vs bone marrow transplantation from unrelated donors (MUD): A single center study. Bone Marrow Transplant 2000; 25 (Suppl 2): S27-S31.
10. Kanteti R, Miller K, McCann J, Roitman D, Morelli J, Hurley C et al. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: A clinical and molecular analysis. Bone Marrow Transplant 1999; 24: 473-481.
11. Majolino I, Pearce R, Taghipour G, Goldstone AH. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: A new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 1997; 15: 509-517.
12. Kessinger A, Vose JM, Bierman PJ, Bishop M, Armitage JO. Peripheral stem cell transplantation in non-Hodgkin's lymphoma patients. J Hematother 1993; 2: 361-362.
13. Cottler-Fox MH, Lapidot T, Petit I, Kollet O, DiPersio JF, Link D et al. Stem cell mobilization. Hematology (Am Soc Hematol Educ Program) 2003, 419-437.
14. Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 29: 285-290.
15. Russell NH, McQuaker G, Stainer C, Byrne JL, Haynes AP. Stem cell mobilisation in lymphoproliferative diseases. Bone Marrow Transplant 1998; 22: 935-940.
16. Gianni AM, Siena S, Bregni M, Tarella C, Stern AC, Pileri A et al. Granulocyte-macrophage-colony-stimulating factor to harvest circulating hemopoietic stem cells for autotransplantation. Lancet 1989; 2: 580-585.
17. Perez-Simon JA, Martin A, Caballero D, Corral M, Nieto MJ, Gonzalez M et al. Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 24: 1279-1283.
18. Bensinger WI, Longin K, Appelbaum F, Rowley S, Weaver C, Lilleby K et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factors (rhGCSF): An analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.
19. Weaver CH, Potz J, Redmond J, Tauer K, Schwartzberg LS, Kaywin P et al. Engraftment and outcome of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell content. Bone marrow Transplant 1997; 19: 1103-1110.
20. Sohn SK, Kim JG, Sung WJ, Kim DH, Suh JS, Lee KS et al. Large-volume leukapheresis using femoral venous access for harvesting peripheral blood stem cells with the Fenwal CS 3000 Plus from normal healthy donors: Predictors of CD34+ cell yield and collection efficiency. J Clin Apheresis 2003; 18: 10-15.
21. Elliott C, Samson DM, Armitage S, Lyttelton MP, McGuigan D, Hargreaves R et al. When to harvest peripheral-blood stem cells after mobilization therapy: Prediction of CD34-positive cell yield by preceding day CD34-positive concentration in peripheral blood. J Clin Oncol 1996; 14: 970-973.
22. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
23. Ketterer N, Salles G, Raba M, Espinouse D, Sonet A, Tremisi P et al. High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148-3155.
24. Siena S, Bregni M, Brando B, Ravagnani F, Bonadonna G, Gianni AM. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989; 74: 1905-1914.
25. Moskowitz CH, Glassman JR, Wuest D, Maslak P, Reich L, Gucciardo A et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998; 4: 311-316.
26. Ketterer N, Salles G, Moullet I, Dumontet C, ElJaafari-Corbin A, Tremisi P et al. Factors associated with successful mobilisation of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103: 235-242.
27. Haas R, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje M et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794.
28. Brown RA, Adkins D, Goodnough LT, Haug JS, Todd G, Wehde M et al. Factors that influence the collection and the engraftment of allogenic peripheral blood stem cells in patients with hematological malignancies. J Clin Oncol 1997; 15: 3067-3074.
29. Micallef IN, Apostolidis J, Rohatiner AZ, Wiggins C, Crawley CR, Foran JM et al. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J 2000; 1: 367-373.
30. Gandhi MK, Jestice K, Scott MA, Bloxham D, Bass G, Marcus RE. The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplant 1999; 23: 9-13.
31. Drake M, Ranaghan L, Morris TC, Nolan L, Desai ZR, Irvine AE et al. Analysis of the effect of prior therapy on progenitor cell yield: Use of chemotherapy scoring system. Br J Haematol 1997; 99: 479.
32. Perry AR, Watts MJ, Peniket AJ, Goldstone AH, Lynch DC. Progenitor cell yields are frequently poor in patients with histologicaly indolent lymphomas especially when mobilised within 6 months of previous chemotherapy. Bone Marrow Transplant 1998; 21: 1201-1205.
33. Schots R, Van Riet I, Damiaens S, Flament J, Lacor P, Staelens Y et al. The absolute number of CD34+ cells predicts the number of hematopoietic stem cells that can be predicted by apheresis. Bone Marrow Transplant 1996; 17: 509-515.
34. Tarella C, Di Nicola M, Caracciolo D, Zallio F, Cuttica A, Omede P et al. High dose ARA-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: An indication for patients at risk for low mobilizaton. Bone Marrow Transplant 2002; 30: 725-732.
35. Benekli M, Hahn T, Shafi F, Qureshi A, Alam AR, Czuczman MS et al. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients. Bone Marrow Transplant 2003; 32: 139-143.
36. Endo T, Sato N, Mogi Y, Koizumi K, Nishio M, Fujimoto K et al. Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 703-707.
37. Gordan LN, Sugrue MW, Lynch JW, Williams KD, Khan SA, Wingard JR et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2003; 44: 815-820.
38. Stockerl-Goldstein KE, Reddy SA, Horning SF, Blume KG, Chao NF, Hu WW et al. Favorable outcome in non-Hodgkin's lymphoma patients with 'poor' mobilization of peripheral blood progenitor cells. Biol Blood Transplant 2000; 6: 506-512.
39. Mavroudis D, Read E, Cottler-Fox M, Couriel D, Molldrem J, Carter C et al. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88: 3223-3229.
40. Stewart DA, Guo D, Luider J, Auer I, Klassen J, Morris D et al. A low CD34+ cell dose predicts relapse and death early following autologous blood stem cell transplantation. Hematology 2001; 6: 19-27.
41. Barrett JA, Ringden O, Zhang M-J, Bashey A, Cahn JY, Cairo MS et al. Effect of nucleated marrow cell dose on relapse and survival in identical twin transplants for leukemia. Blood 2000; 95: 3323-3327.
42. Carlo-Stella C, Di Nicola M, Milani R, Guidetti A, Magni M, Milanesi M et al. Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers. Blood 2004; 103: 3287-3295.
43. Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD et al. The use of AMD3100 plus G-CSF for autologous hemopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867-1874.